{"id":15726,"date":"2024-02-21T10:14:13","date_gmt":"2024-02-21T09:14:13","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=15726"},"modified":"2026-06-10T20:51:54","modified_gmt":"2026-06-10T18:51:54","slug":"altavo-concludes-series-a-for-the-development-of-its-artificial-voice","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2024-en\/altavo-concludes-series-a-for-the-development-of-its-artificial-voice\/","title":{"rendered":"Altavo completes Series A for the development of its artificial voice"},"content":{"rendered":"

Altavo GmbH, an AI-based voice reha\u00adbil\u00adi\u00adta\u00adtion startup founded in 2021, suc\u00adcess\u00adfully closed its Series A financ\u00ading round on Feb\u00adru\u00adary 1, 2024. A Euro\u00adpean con\u00adsor\u00adtium led by OCCIDENT is invest\u00ading \u20ac 5.0 mil\u00adlion in the devel\u00adop\u00adment of Altavo\u2019s inno\u00adv\u00ada\u00adtive arti\u00adfi\u00adcial voice. <\/strong><\/p>\n

Altavo\u2019s Arti\u00adfi\u00adcial Voice is a med\u00adical device designed to restore the nat\u00adural sound\u00ading voice of voice\u00adless peo\u00adple, for exam\u00adple fol\u00adlow\u00ading laryn\u00adgec\u00adtomy or arti\u00adfi\u00adcial res\u00adpi\u00adra\u00adtion. The pro\u00adpri\u00adetary \u201cSilent Speech\u201d tech\u00adnol\u00adogy devel\u00adoped for this pur\u00adpose in col\u00adlab\u00ado\u00adra\u00adtion with the Tech\u00adni\u00adcal Uni\u00adver\u00adsity of Dres\u00adden is based on non-inva\u00adsive radar sen\u00adsor tech\u00adnol\u00adogy and the lat\u00adest neural net\u00adwork architectures. <\/p>\n

In addi\u00adtion to the lead investor OCCIDENT from Munich, Novalis Biotech (Ghent, Bel\u00adgium), bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen and oth\u00aders are also invest\u00ading in the cur\u00adrent, sig\u00adnif\u00adi\u00adcantly over\u00adsub\u00adscribed round. In addi\u00adtion, almost all seed investors from the first financ\u00ading round in Decem\u00adber 2021 are par\u00adtic\u00adi\u00adpat\u00ading with a fol\u00adlow-up invest\u00adment, includ\u00ading TGFS Tech\u00adnolo\u00adgiegr\u00fcn\u00adder\u00adfonds Sach\u00adsen, High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), Sax\u00ado\u00adnia Sys\u00adtems Hold\u00ading and TUDAG TU Dres\u00adden AG. <\/p>\n

The Series A that has now been con\u00adcluded is intended to finance the fur\u00adther estab\u00adlish\u00adment of the com\u00adpany, prod\u00aduct devel\u00adop\u00adment, the clin\u00adi\u00adcal approval study and inter\u00adna\u00adtion\u00adal\u00adiza\u00adtion. Altavo\u2019s tech\u00adnol\u00adogy not only promises a break\u00adthrough in the reha\u00adbil\u00adi\u00adta\u00adtion of voice\u00adless peo\u00adple, but also opens up com\u00adpletely new pos\u00adsi\u00adbil\u00adi\u00adties in silent com\u00admu\u00adni\u00adca\u00adtion and human-tech\u00adnol\u00adogy interaction. <\/p>\n

\u201cWe are delighted to have secured a strong Euro\u00adpean investor group for our vision of giv\u00ading voice\u00adless peo\u00adple their voice back. With the financ\u00ading now com\u00adpleted, our clin\u00adi\u00adcal sup\u00adport\u00aders and our team, we believe we are ide\u00adally posi\u00adtioned for the tech\u00adni\u00adcal and clin\u00adi\u00adcal devel\u00adop\u00adment ahead of us.<\/em>\u201d
\nRudolf von B\u00fcnau, Man\u00adag\u00ading Direc\u00adtor and Co-Founder, Altavo GmbH<\/p>\n

\u201cWith our invest\u00adment in Altavo, we are back\u00ading an expe\u00adri\u00adenced team with a con\u00advinc\u00ading prod\u00aduct vision. Our aim as a long-term investor is to sup\u00adport the team on its way to the mar\u00adket and to enable the real\u00adiza\u00adtion of the com\u00adpa\u00adny\u2019s ambi\u00adtious goals.<\/em>\u201d
\nMirco M\u00fcller, Junior Invest\u00adment Man\u00adager, OCCIDENT<\/p>\n

\u201cWe are impressed by Altavo\u2019s highly expe\u00adri\u00adenced and ded\u00adi\u00adcated team and its inno\u00adv\u00ada\u00adtive, poten\u00adtially dis\u00adrup\u00adtive tech\u00adnol\u00adogy. We look for\u00adward to sup\u00adport\u00ading the com\u00adpany in bring\u00ading this unique solu\u00adtion to peo\u00adple with voice loss.<\/em>\u201d
\nJaroslav Belot\u00adserkovsky, Invest\u00adment Man\u00adager, Novalis Biotech<\/p>\n

\u201cFor us, Altavo, with its loca\u00adtions in Dres\u00adden and Jena, is a prime exam\u00adple of the inno\u00adv\u00ada\u00adtive strength of the Cen\u00adtral Ger\u00adman region and the suc\u00adcess\u00adful col\u00adlab\u00ado\u00adra\u00adtion between start-ups and uni\u00adver\u00adsi\u00adties. We are delighted to invest in a promis\u00ading med\u00adical tech\u00adnol\u00adogy com\u00adpany that ben\u00ade\u00adfits from and com\u00adple\u00adments the exist\u00ading struc\u00adtures at both loca\u00adtions.<\/em>\u201d
\nMichael Thiele, Invest\u00adment Man\u00adager, bm | t Beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen GmbH and S\u00f6ren Schus\u00adter, Man\u00adag\u00ading Direc\u00adtor, TGFS Tech\u00adnolo\u00adgiegr\u00fcn\u00adder\u00adfonds Sachsen<\/p>\n

About Altavo<\/h4>\n

Altavo GmbH<\/a> is a med\u00adical tech\u00adnol\u00adogy start-up founded in Feb\u00adru\u00adary 2021 and based in Dres\u00adden. Based on non-inva\u00adsive radar sen\u00adsor tech\u00adnol\u00adogy and arti\u00adfi\u00adcial intel\u00adli\u00adgence, Altavo devel\u00adops pros\u00adthet\u00adics to improve the reha\u00adbil\u00adi\u00adta\u00adtion of voice\u00adless and vocally impaired patients. At its sites in Dres\u00adden and Jena, Altavo cur\u00adrently employs 15 peo\u00adple with many years of expe\u00adri\u00adence in the fields of AI \/ data sci\u00adence, speech tech\u00adnol\u00adogy, high-fre\u00adquency tech\u00adnol\u00adogy, med\u00adical tech\u00adnol\u00adogy and voice ther\u00adapy. Altavo coop\u00ader\u00adates with the Chair of Speech Tech\u00adnol\u00adogy and Cog\u00adni\u00adtive Sys\u00adtems and the Chair of High Fre\u00adquency Tech\u00adnol\u00adogy at the Tech\u00adni\u00adcal Uni\u00adver\u00adsity of Dres\u00adden. The col\u00adlab\u00ado\u00adra\u00adtion is funded by the Fed\u00aderal Min\u00adistry of Edu\u00adca\u00adtion and Research (BMBF) in the \u201cPromise-AI\u201d project and by the S\u00e4ch\u00adsis\u00adche Auf\u00adbaubank (SAB) in the \u201cSEMECO-B3: MUSIK\u201d project.
\nPress con\u00adtact: Rudolf v. B\u00fcnau, rudolf.vonbuenau@altavo.eu <\/p>\n

About OCCIDENT<\/h4>\n

OCCIDENT<\/a> is an inter\u00adna\u00adtional ven\u00adture cap\u00adi\u00adtal investor with offices in Munich and Zug, is owner-man\u00adaged and invests its own assets. The aim is to make a pos\u00adi\u00adtive con\u00adtri\u00adbu\u00adtion to soci\u00adety through sus\u00adtain\u00adable and mean\u00ading\u00adful invest\u00adments. OCCIDENT invests in inno\u00adv\u00ada\u00adtive deep-tech start-ups with excel\u00adlent tech\u00adnolo\u00adgies, broad appli\u00adca\u00adtion pos\u00adsi\u00adbil\u00adi\u00adties and the poten\u00adtial for value-gen\u00ader\u00adat\u00ading fur\u00adther devel\u00adop\u00adment in the fields of life sci\u00adences, indus\u00adtrial tech and dig\u00adi\u00adtal. OCCIDENT acts as a long-term enabler for highly inno\u00adv\u00ada\u00adtive start-ups and vision\u00adary found\u00ading teams. <\/p>\n

About Novalis Biotech<\/h4>\n

Novalis Biotech<\/a> (Ghent, Bel\u00adgium) is an early-stage ven\u00adture cap\u00adi\u00adtal investor that invests in tech\u00adnolo\u00adgies that are rev\u00ado\u00adlu\u00adtion\u00adiz\u00ading health\u00adcare. The com\u00adpa\u00adny\u2019s core com\u00adpe\u00adtence lies in the dig\u00adi\u00adtal\u00adiza\u00adtion of life sci\u00adences, with a focus on bioin\u00adfor\u00admat\u00adics, genomics and diag\u00adnos\u00adtics. Novalis believes in the appli\u00adca\u00adtion of inno\u00adv\u00ada\u00adtive tech\u00adnolo\u00adgies to advance the pre\u00adven\u00adtion, diag\u00adno\u00adsis or treat\u00adment of disease.
\nFor more infor\u00adma\u00adtion, please visit www.noval.is<\/a> <\/p>\n

About bm|t<\/h4>\n

bm|t<\/a>, based in Erfurt, is a sub\u00adsidiary of Th\u00fcringer Auf\u00adbaubank and the lead\u00ading address for invest\u00adments in Thuringia. The bm|t cur\u00adrently man\u00adages twelve funds with a total vol\u00adume of around EUR 445 mil\u00adlion, which invest in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies in almost all sec\u00adtors and in all phases of com\u00adpany devel\u00adop\u00adment \u2014 both in the start-up and growth phases or in com\u00adpany suc\u00adces\u00adsion situations.
\nPress con\u00adtact: Michael Thiele, michael.thiele@bm\u2011t.de <\/p>\n

About the TGFS Technologiegr\u00fcnderfonds Sachsen<\/h4>\n

TGFS<\/a> is an equity investor for knowl\u00adedge-based, tech\u00adnol\u00adogy-ori\u00adented start-ups in Sax\u00adony. It is the lead\u00ading start-up financier in the Free State of Sax\u00adony and sup\u00adports teams with ven\u00adture cap\u00adi\u00adtal and man\u00adage\u00adment sup\u00adport in both the seed and start-up phases. An invest\u00adment by the TGFS gives port\u00adfo\u00adlio com\u00adpa\u00adnies access to other inter\u00adna\u00adtional investors. The fund was first launched in 2008 by the Free State of Sax\u00adony (with ERDF fund\u00ading, among other things) and Saxon finan\u00adcial insti\u00adtu\u00adtions and has since sup\u00adported over 100 start-ups in what is now the third gen\u00ader\u00ada\u00adtion of the fund.
\nPress con\u00adtact: S\u00f6ren Schus\u00adter, Tel. +49 172 2001097, soeren.schuster@cfh.de <\/p>\n

About High-Tech Gr\u00fcnderfonds<\/h4>\n

The seed investor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF)<\/a> finances tech\u00adnol\u00adogy start-ups with growth poten\u00adtial and has sup\u00adported more than 700 start-ups since 2005. With the launch of the fourth fund, HTGF has around 1.4 bil\u00adlion euros under man\u00adage\u00adment. The team of expe\u00adri\u00adenced invest\u00adment man\u00adagers and start-up experts sup\u00adports the young com\u00adpa\u00adnies with know-how, entre\u00adpre\u00adneur\u00adial spirit and pas\u00adsion. The focus is on high-tech start-ups in the fields of dig\u00adi\u00adtal tech, indus\u00adtrial tech, life sci\u00adences, chem\u00adi\u00adcals and related busi\u00adness areas. To date, exter\u00adnal investors have invested around 5 bil\u00adlion euros in the HTGF port\u00adfo\u00adlio in more than 2,000 fol\u00adlow-up financ\u00ading rounds. In addi\u00adtion, the fund has already suc\u00adcess\u00adfully sold shares in more than 170 com\u00adpa\u00adnies. Fund investors in the pub\u00adlic-pri\u00advate part\u00adner\u00adship include the Ger\u00adman Fed\u00aderal Min\u00adistry for Eco\u00adnomic Affairs and Cli\u00admate Pro\u00adtec\u00adtion, KfW Cap\u00adi\u00adtal and 45 com\u00adpa\u00adnies from a wide range of sectors.
\nPress con\u00adtact: Tobias Jacob, Senior Mar\u00adket\u00ading & Com\u00admu\u00adni\u00adca\u00adtions Manager
\nPhone +49 228 82300 121, t.jacob@htgf.de <\/p>\n","protected":false},"excerpt":{"rendered":"

Altavo GmbH, a startup for AI-based voice reha\u00adbil\u00adi\u00adta\u00adtion, has suc\u00adcess\u00adfully closed its Series A financ\u00ading round of \u20ac 5 million. <\/p>\n","protected":false},"author":2,"featured_media":15723,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[248],"tags":[176,177,210,159,171,175,174],"class_list":["post-15726","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2024-en","tag-bm-t-en","tag-bmt-en","tag-investeepartner","tag-investment-en","tag-thuringia","tag-thuringia-growth-fund","tag-wbf-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=15726"}],"version-history":[{"count":1,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15726\/revisions"}],"predecessor-version":[{"id":18202,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15726\/revisions\/18202"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/15723"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=15726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=15726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=15726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}